ABNCoV2 has met its primary objective in Phase 3, demonstrating non-inferiority to the Comirnaty® mRNA-vaccine. Additionally, safety data from 4,205 individuals followed up for 2 months post vaccination showed ABNCoV2 to be well-tolerated with no serious adverse events being reported.
Best-in-class 12-month durable antibody responses have been reported for Ph2.
AdaptVac, as part of the EU H2020 funded PREVENT-nCoV consortium, is focused on developing a SARS-CoV-2 (COVID-19) vaccine using our capsid Virus-Like Particle (cVLP) display technology.
The vaccine, ABNCoV2, has been exclusively licensed to Bavarian Nordic. Phase II study with 210 persons has been completed successfully, and DKK 800M has been committed by the Danish Ministry of Health to support the on-going PhIII trial.
Nipah and filovirus vaccines
The VICI-DISEASE consortium’s main objective is to develop a vaccine candidate portfolio and perform a clinical proof-of-concept study, to enable stocks of vaccine candidates ready for clinical validation in large-scale efficacy trials in case of pandemic outbreaks.
The primary target will be Nipah virus, a virus causing high-mortality disease with no vaccines or treatments available. This capsid Virus-Like Particle (cVLP) vaccine will be uniquely positioned to help control and prevent future Nipah virus epidemics and pandemics.
The VICI-Disease consortium consists of AdaptVac, ExpreS2ion, Friedrich-Loeffler-Institut (FLI), the Radboud university medical center (RUMC) and University of Copenhagen (UCPH). Furthermore, PSG Institute of Medical Sciences and Research, Centre de Recherches Médicales de Lambaréné (CERMEL) and NIH/NIAID are associated participants in this grant-sponsored development project.
HER2+ Cancer vaccine
ES2B-C001, licensed to ExpreS2ion Biotechnologies, is currently in GMP manufacture.
In December 2021 and January 2022, positive preclinical proof-of-concept results were announced. In these studies, ES2B-C001 demonstrated a strong tumor-growth inhibiting effect in a mouse model and human cancer cells (December 2021), as well as in HER2-transgenic preventive and therapeutic tumor mice models (January 2022).Further excellent preclinical results were announced in May 2022, based on a new study in which HER2-transgenic mice were injected with HER2-positive tumors followed by vaccination every two weeks one week after challenge. All control mice had lung nodules, whereas all mice vaccinated with ES2B-C001 formulated in an adjuvant were metastasis-free. Furthermore, 73% of mice vaccinated with ES2B-C001 without adjuvant were metastasis-free, the remaining had only 1-2 lung nodules.
Pre-clinical GMP Ph1 Ph2 Ph3
Nipah & filovirus
Funded to Ph1/2a
Funded to Ph2